Pharmadrug (TSE:PHRX) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
PharmaDrug has commenced a clinical study for PD-001, a patented enteric-coated cepharanthine, aimed at treating viral infections. The study will assess bioavailability and pharmacokinetics in volunteers, with the goal to improve upon the drug’s traditionally low bioavailability. Positive results could lead to Phase 2 trials and attract potential pharmaceutical partners or investors.
For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.